Search

Displaying results 5151 - 5160 of 10000 in total
  1. Drug

    Oxyphenbutazone

    go.drugbank.com/drugs/DB03585
    ApprovedWithdrawn

    Oxyphenbutazone was withdrawn from the Canadian market in March 1985 due to concerns regarding bone marrow suppression.

  2. Drug

    Copper Cu-64

    go.drugbank.com/drugs/DB13980
    Approved

    [T604] It is used in molecular radiotherapy and positron emission tomography. … Copper-64 is a radiopharmaceutical usually found in the +2 oxidation state as the complexes including the +1 state tend to be more unstable.

  3. Drug

    AM365

    go.drugbank.com/drugs/DB06564
    Experimental

    Detiviciclovir (AM365) is an antiviral nucleoside analogue.

  4. Drug

    LAX-101

    go.drugbank.com/drugs/DB05301
    Investigational

    The molecules of EPA found in LAX-101 are identical to the molecules of EPA found in fish oil food supplements. … The active molecule in LAX-101 is Eicosapentaenoic Acid (EPA). All molecules of EPA are identical.

  5. Drug

    IR501

    go.drugbank.com/drugs/DB06464
    Experimental

    It was last known to be in phase III clinical trials. … IR501 (Ravax) is a potential first-in-class vaccine for the treatment of Rheumatoid Arthritis. It specifically targets autoreactive T-cells, reducing their activity.

  6. Drug

    Banoxantrone

    go.drugbank.com/drugs/DB04975
    Investigational

    Banoxantrone is a highly selective bioreductive drug that is activated in, and is preferentially toxic to, hypoxic cells in tumours. … Banoxantrone was also efficacious in tumour models when administered in combination with either cisplatin or chemoradiation. [A3115]

  7. Drug

    Befunolol

    go.drugbank.com/drugs/DB09013
    Experimental

    Befunolol is a beta blocker introduced in 1983 by Kakenyaku Kakko. It is currently in experimental status, and is being tested for the management of open angle glaucoma.

  8. Drug

    STC3141

    go.drugbank.com/drugs/DB16475
    Investigational

    STC3141, was investigated in clinical trial NCT04880694 to evaluate its safety and effect in subjects with severe COVID-19 pneumonia.

  9. Drug

    Trevogrumab

    go.drugbank.com/drugs/DB15159
    Investigational

    and Healthy Adult Men). … Trevogrumab is under investigation in clinical trial NCT02943239 (Study of Safety, Tolerability, and Pharmacokinetics of REGN2477 Alone and in Combination With REGN1033 in Healthy Postmenopausal Women

  10. Drug

    AT2220

    go.drugbank.com/drugs/DB05200
    Investigational

    AT2220 has been shown to increase GAA activity in cell lines derived from Pompe patients and in transfected cells expressing misfolded forms of GAA. … AT2220 is an experimental, oral therapy for the treatment of Pompe disease and belongs to a class of molecules known as pharmacological chaperones.